Evidence map›Paper›PMID 42306282›Full record

ArticleTherapeutics2026

HIV-Associated Cryptococcal Meningitis: A Call for Action for New Treatment Options.

Samuel Okurut, David B Meya

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Samuel OkurutResearch Department, Infectious Diseases Institute, Makerere University, Kampala P. O. Box 22418, Uganda.
David B MeyaResearch Department, Infectious Diseases Institute, Makerere University, Kampala P. O. Box 22418, Uganda.

Funding

Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related MeningitisR01NS086312 · NINDS · UNIVERSITY OF MINNESOTA · PI David R Boulware, David Bisagaya Meya · 2013 to 2026
$8.3M
TB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory TherapiesR01AI162786 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R, MEYA, DAVID BISAGAYA · 2021 to 2025
$3.3M
Improving outcomes in HIV-associated opportunistic infections using CNS pharmacokinetics and pharmacodynamicsR01NS139908 · NINDS · UNIVERSITY OF MINNESOTA · PI Melanie Rae Nicol · 2024 to 2026
$2.0M
Minnesota-Makerere-Mbarara Neuro-Infectious Disease Research Training ConsortiumD43TW012266 · FIC · UNIVERSITY OF MINNESOTA · PI David R Boulware, David Bisagaya Meya · 2024 to 2026
$747k
FIC NIH HHS D43 TW012266NIAID NIH HHS R01 AI162786NINDS NIH HHS R01 NS086312NINDS NIH HHS R01 NS139908
6 · The paper itself

Abstract

Cryptococcal meningitis occurs in 62% of persons with HIV-associated meningitis, making Cryptococcus an important cause of meningitis among adults with advanced HIV disease in regions with elevated prevalence of HIV. Despite efforts to advance treatment, the in-hospital death rate of 19% remains unprecedentedly high. Aggregate published clinical trial data evaluating cryptococcosis treatment with survival as the primary endpoint show a significant reduction in the proportion of survivors from diagnosis to 88.5% at 2 weeks of treatment and further to 74% survival at 10 weeks of follow-up (

Indexed as

antifungal therapyclinical trialscryptococcal meningitishuman immunodeficiency virusmortality improved regimensurvival

Identifiers

PMID42306282
PMCPMC13268590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.